Tysabri is a medicine for treating adults with multiple sclerosis (MS) that is not sufficiently controlled with another disease-modifying therapy or is rapidly getting worse. Multiple sclerosis is a disease of the nerves, in which inflammation destroys the protective sheath surrounding nerves and damages the nerves themselves. Tysabri is used in relapsing-remitting MS, a type of MS in which the patient has attacks (relapses) between periods of stable symptoms (remissions). It contains the active substance natalizumab.
Therapeutic Indication
### Therapeutic indication Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: - Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Therapeutic Area (MeSH)
ATC Code
L04AG03
ATC Item
natalizumab
Pharmacotherapeutic Group
Monoclonal antibodies
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| natalizumab | N/A | 那他珠单抗 |
EMA Name
Tysabri
Medicine Name
Tysabri
Aliases
N/A
